Austar Lifesciences Limited provided group earnings guidance for the six months ended June 30, 2016. The group is expected to incur a loss attributable to the shareholders of the company for the six months ending June 30, 2016, as compared to a profit attributable to the shareholders of the Company of approximately RMB 10,144,000 for the corresponding period in 2015. Such loss is mainly attributable to (i) prolonged execution time for certain projects undertaken by the Group during the period resulting in a decrease in the overall revenue of the Group and an increase in budgeted costs as compared with the corresponding period in 2015; and (ii) decrease in the overall gross profit margin for the projects undertaken by the Group as compared with the corresponding period in 2015 as certain projects with a relatively lower gross profit margin being undertaken by the Group during the period for the purpose of retaining customers.